NAD+ Nicotinamide Adenine Dinucleotide — Class II drug recall D-0719-2022
Terminated recall by Olympia Compounding Pharmacy dba Olympia Pharmacy, reported 2022-03-30, distributed nationwide. Product found to be Sub Potent or Exceeded reconstitution time
| Recall number | D-0719-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Olympia Compounding Pharmacy dba Olympia Pharmacy, Orlando, FL, United States |
| Recall initiated | 2022-03-08 |
| Classified | 2022-03-29 |
| Reported by FDA | 2022-03-30 |
| Terminated | 2023-10-04 |
| Distributed | Nationwide (US) |
| Quantity | 2,634 vials |
| NDC | 73198-0083-00 |
| Lot numbers | C41008, D24005 |
| Expiration dates | 2022-03-08, 2022-04-05 |
Product
NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose 500 mg per vial, Each ML contains: 0.288% Sodium Phosphate Monobasic USP, 0.42% Sodium Phosphate Dibasic USP, 5% Mannitol USP, Sterile Water for Injection USP, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835 NDC: 73198-0083-00
Reason for recall
Product found to be Sub Potent or Exceeded reconstitution time
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0719-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.